How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about pembrolizumab

Pembrolizumab (Keytruda, Merck Sharp & Dohme)

Marketing authorisation

Pembrolizumab has a marketing authorisation for 'the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy'.

Recommended dose and schedule

200 mg by intravenous infusion every 3 weeks, or 400 mg by intravenous infusion every 6 weeks, until disease progression or unacceptable toxicity.

Price

£2,630 per 100 mg vial (excluding VAT; company submission).

The company has a commercial arrangement (simple discount patient access scheme), which would have applied if the technology had been recommended for routine commissioning. This makes pembrolizumab available at a reduced cost. The financial terms of the agreement are commercial in confidence.

While available in the Cancer Drugs Fund (see technology appraisal 519), pembrolizumab has a commercial arrangement (managed access agreement including a commercial access agreement).